JP5118965B2 - 植物成分を必要とする治療方法 - Google Patents

植物成分を必要とする治療方法 Download PDF

Info

Publication number
JP5118965B2
JP5118965B2 JP2007525450A JP2007525450A JP5118965B2 JP 5118965 B2 JP5118965 B2 JP 5118965B2 JP 2007525450 A JP2007525450 A JP 2007525450A JP 2007525450 A JP2007525450 A JP 2007525450A JP 5118965 B2 JP5118965 B2 JP 5118965B2
Authority
JP
Japan
Prior art keywords
phytosterol
phytostanol
ester
fish oil
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007525450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509904A5 (enExample
JP2008509904A (ja
Inventor
アヴィドア シュルマン，
ドリ ペレド，
トザフラ コーヘン，
オーリー ファルカシュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frutarom Ltd
Original Assignee
Enzymotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd filed Critical Enzymotec Ltd
Publication of JP2008509904A publication Critical patent/JP2008509904A/ja
Publication of JP2008509904A5 publication Critical patent/JP2008509904A5/ja
Application granted granted Critical
Publication of JP5118965B2 publication Critical patent/JP5118965B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
JP2007525450A 2004-08-10 2005-08-10 植物成分を必要とする治療方法 Expired - Fee Related JP5118965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL163447 2004-08-10
IL16344704 2004-08-10
PCT/IL2005/000861 WO2006016363A2 (en) 2004-08-10 2005-08-10 Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions

Publications (3)

Publication Number Publication Date
JP2008509904A JP2008509904A (ja) 2008-04-03
JP2008509904A5 JP2008509904A5 (enExample) 2012-02-23
JP5118965B2 true JP5118965B2 (ja) 2013-01-16

Family

ID=35064686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525450A Expired - Fee Related JP5118965B2 (ja) 2004-08-10 2005-08-10 植物成分を必要とする治療方法

Country Status (10)

Country Link
US (1) US8772270B2 (enExample)
EP (1) EP1796726A2 (enExample)
JP (1) JP5118965B2 (enExample)
KR (1) KR101323513B1 (enExample)
CN (1) CN101039585B (enExample)
AU (1) AU2005270831B2 (enExample)
BR (1) BRPI0513461A2 (enExample)
IL (1) IL181234A0 (enExample)
RU (1) RU2394576C2 (enExample)
WO (1) WO2006016363A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147942A0 (en) * 2002-01-31 2002-08-14 Enzymotec Ltd Method of fractionation of phytosterol esters in oil and products obtained thereby
AU2005270831B2 (en) 2004-08-10 2011-08-25 Enzymotec Ltd. Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
ITBA20060049A1 (it) * 2006-08-02 2008-02-03 Pierre S R L Integratore alimentare a base di licopene biologico e procedimento per l'ottenimento del licopene biologico.
MY184667A (en) * 2007-07-23 2021-04-15 Malaysian Palm Oil Board An antiviral composition
US20090202704A1 (en) * 2008-02-13 2009-08-13 Kao Corporation Postprandial hyperglycemia-improving agent
EP2419115B1 (fr) * 2009-04-15 2014-12-31 Actigenomics S.A. Composition destinee a la regulation du metabolisme des lipides
US20110160168A1 (en) 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
WO2011120766A1 (en) 2010-03-29 2011-10-06 Unilever Nv Edible tomato-based product comprising orally bioavailable endogenous micronutrients
US8039025B1 (en) * 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers
CN103054025A (zh) * 2013-01-04 2013-04-24 浙江大学 防治前列腺疾病的保健食品组合物
EP2968990A4 (en) * 2013-03-15 2016-08-24 Nutramax Lab Inc COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL
WO2014143127A1 (en) 2013-03-15 2014-09-18 Differential Drug Development Associates Llc Emulsion formulations
JP2015003877A (ja) * 2013-06-20 2015-01-08 国立大学法人 筑波大学 ヒドロキシチロゾール又はその塩を含む組成物
AU2016367036B2 (en) * 2015-12-09 2019-04-18 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
EP3231421A1 (en) * 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
KR102139994B1 (ko) * 2017-10-25 2020-07-31 대구대학교 산학협력단 스티그마스테롤을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
CN109513006A (zh) * 2018-12-18 2019-03-26 江苏大学附属医院 一种治疗代谢综合征发病药物及其测定方法
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248921C3 (de) 1972-10-05 1981-11-12 Harburger Oelwerke Brinckman & Mergell, 2100 Hamburg Verfahren zur Herstellung eines Gemisches aus pflanzlichen und tierischen Ölen bzw. Fetten und Fettsäuresterinestern
US4064236A (en) 1975-12-23 1977-12-20 Merck & Co., Inc. Peptide carbazates and pharmaceutical composition
DE3117934A1 (de) 1981-05-06 1982-12-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel
ATE22328T1 (de) 1981-05-07 1986-10-15 Unilever Nv Behandlung von fetten.
DE3225705A1 (de) 1982-07-09 1984-01-12 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum ausbringen von pflanzenschutzmittelspritzbruehen durch verspruehen und verpackungseinheit fuer konzentrate
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
JPS60136596A (ja) 1983-12-26 1985-07-20 Suntory Ltd ペプチド及びこれを有効成分とする利尿剤
EP0195311B2 (en) 1985-03-06 1996-01-17 Yoshikawa Oil & Fat Co., Ltd. Process for preparing fatty acid esters
FI851609A0 (fi) 1985-04-23 1985-04-23 Valio Meijerien Foerfarande foer framstaellning av mjoelkbaserade kliniska naeringspreparat.
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
JP2925391B2 (ja) 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
RU2107692C1 (ru) 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5512691A (en) 1994-11-07 1996-04-30 Eastman Chemical Company Process for the production of tocopherol concentrates
US5843499A (en) 1995-12-08 1998-12-01 The United States Of America As Represented By The Secretary Of Agriculture Corn fiber oil its preparation and use
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
FR2750606B1 (fr) 1996-07-03 1999-01-29 Maurel Sante Complexes organometalliques a base de sitosterols et de diglycerides et compositions pharmaceutiques en contenant
US6046022A (en) * 1996-09-30 2000-04-04 Peking University Methods and compositions employing red rice fermentation products
US5998396A (en) * 1996-11-05 1999-12-07 Riken Vitamin Co., Ltd. Oil solubilized solutions and foods containing phytosterols and process for their production
FI107538B (fi) 1997-02-26 2001-08-31 Raisio Benecol Oy Menetelmä stanoliesterien valmistamiseksi
FR2761887B1 (fr) 1997-04-11 1999-06-18 Roland Asmar Medicament visant a la prevention multifactorielle des maladies cardiovasculaires
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
ES2229443T3 (es) 1997-08-22 2005-04-16 Unilever N.V. Procedimiento para la produccion de esteres de estanol.
ATE531381T1 (de) * 1997-08-29 2011-11-15 Ricex Company Inc Stabilisierte reiskleiederivate zur behandlung von diabetes
US5993866A (en) 1997-09-12 1999-11-30 Shapira; Niva Process of making food products having reduced methionine ratios
AU8760898A (en) * 1997-09-24 1999-04-12 Enzymotec Ltd. Surfactant-lipase complex immobilized on insoluble matrix
IL129086A0 (en) 1999-03-22 2000-02-17 Enzymotec Ltd Surfactant-lipase complex immobilized on insoluble matrix
CA2279402C (en) 1998-03-24 2009-04-07 Kao Corporation Oil or fat composition containing phytosterol
US6025348A (en) * 1998-04-30 2000-02-15 Kao Corporation Oil and fat composition containing phytosterol
US6139897A (en) * 1998-03-24 2000-10-31 Kao Corporation Oil or fat composition containing phytosterol
FI111513B (fi) 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US6087353A (en) * 1998-05-15 2000-07-11 Forbes Medi-Tech Inc. Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like
SE514725C2 (sv) 1998-06-02 2001-04-09 Karlshamns Ab Fraktioneringsförfarande
NZ333817A (en) * 1998-08-25 2000-09-29 Mcneil Ppc Inc Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
FI982125A0 (fi) 1998-10-01 1998-10-01 Hk Ruokatalo Oyj Terveyteen myönteisesti vaikuttava elintarvike
WO2002060272A1 (en) 2001-01-29 2002-08-08 Redeem, Inc. Anticholesterolemic edible oil
US6277431B1 (en) 1998-10-14 2001-08-21 Redeem, Inc. Anticholesterolemic edible oil
US6113972A (en) * 1998-12-03 2000-09-05 Monsanto Co. Phytosterol protein complex
US6129945A (en) * 1998-12-10 2000-10-10 Michael E. George Methods to reduce free fatty acids and cholesterol in anhydrous animal fat
CH692263A5 (de) 1999-04-29 2002-04-30 Europ Foodtec Gmbh Fleischprodukte mit omega-3-Fettsäure und Vitamin.
JP4526147B2 (ja) 1999-05-26 2010-08-18 株式会社Adeka 植物ステロール脂肪酸エステル含有組成物の製造方法
US6080173A (en) 1999-05-26 2000-06-27 Idx Medical Ltd. Tissue punching instrument
EP1180545B2 (en) 1999-05-26 2018-05-09 Adeka Corporation Vegetable sterol-containing fat compositions and process for producing the same
US6365211B1 (en) * 1999-06-18 2002-04-02 The Procter & Gamble Co. Cooking aid with reduced foaming
CA2382262C (en) 1999-08-30 2004-12-07 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
AU1260801A (en) 1999-11-03 2001-05-14 Forbes Medi-Tech Inc. Compositions comprising edible oils or fats and phytosterols and/or phytostanolssubstantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease and its underlying conditions
NZ519063A (en) 1999-11-05 2003-11-28 Raisio Benecol Oy Edible fat blends of olive oil containing sterol or stanol fatty acid esters
DK1121928T3 (da) * 2000-01-31 2008-03-17 Haerting S A Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider
JP2001247473A (ja) 2000-03-06 2001-09-11 Kao Corp インスリン抵抗性改善剤
US20020132035A1 (en) * 2001-01-10 2002-09-19 Dov Tamarkin Synthetic fat composition
US20020016317A1 (en) 2000-03-27 2002-02-07 Schul David Allen Sterol ester compositions
IL135466A (en) 2000-04-04 2006-07-05 Sobhi Basheer Process for selective alcoholysis of free sterols in fat-based product with an insoluble matrix-immobilized lipase complex
JP4911815B2 (ja) 2000-04-28 2012-04-04 株式会社Ａｄｅｋａ 植物ステロール含有油脂組成物
US20020025349A1 (en) * 2000-05-02 2002-02-28 Brindavanam Narasimha Baba Novel herbal composition for diabetes patients and a process for producing the same
US7147859B2 (en) * 2000-05-15 2006-12-12 Laboratorios Biosintetica Ltda. Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
JP3774110B2 (ja) * 2000-07-19 2006-05-10 花王株式会社 食用油脂及びその製造法
JP4031219B2 (ja) 2000-08-08 2008-01-09 花王株式会社 油脂組成物
CA2417971C (en) * 2000-08-08 2010-01-19 Kao Corporation Oil/fat composition
BG540Y1 (bg) 2000-08-18 2002-06-28 "Ел Би Булгарикум" ЕАД Диетична десертна млечна напитка
CN1204238C (zh) 2000-10-18 2005-06-01 李大鹏 从核桃仁中提取的核桃仁油组合物及其药物制剂
SE523094C2 (sv) * 2001-01-11 2004-03-30 Karlshamns Ab Förfarande för framställning av en fettkomposition som innehåller sterolestrar, fria steroler och glycerider, fettkomposition framställd genom förfarandet samt fettkompositionens användning
KR100344400B1 (ko) 2001-01-18 2002-07-24 주식회사 온바이오 고함량의 디글리세라이드를 포함하는 유지 조성물의 제조방법
US6667068B2 (en) * 2001-01-29 2003-12-23 Kraft Foods Holdings, Inc. Method for preparing solid milk product
GB0104074D0 (en) 2001-02-19 2001-04-04 Novartis Ag New composition
US6956058B2 (en) * 2001-04-26 2005-10-18 Kao Corporation Method for improving insulin resistance
JP4995377B2 (ja) * 2001-04-26 2012-08-08 花王株式会社 油脂組成物
EP1395124B1 (en) * 2001-05-23 2006-04-12 Nutricopia, Inc. Nutritional frozen dessert and methods of manufacture
GB0114014D0 (en) 2001-06-08 2001-08-01 Novartis Nutrition Ag Compostion and use
US6787151B2 (en) 2001-08-10 2004-09-07 Lipton, Division Of Conopco, Inc. Composition for lowering blood cholesterol
IL147942A0 (en) 2002-01-31 2002-08-14 Enzymotec Ltd Method of fractionation of phytosterol esters in oil and products obtained thereby
ES2193874B1 (es) 2002-04-03 2005-03-01 Puleva Biotech, S.A. Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
JP3836819B2 (ja) 2002-07-01 2006-10-25 花王株式会社 酸性水中油型乳化組成物
JP2004210652A (ja) 2002-12-27 2004-07-29 Kao Corp 糖尿病患者における脂質代謝改善剤
US20060233863A1 (en) 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
IL155136A0 (en) * 2003-02-10 2003-10-31 Enzymotec Ltd A composition for reducing blood cholesterol and triglycerides
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements
US20090232916A1 (en) * 2004-08-09 2009-09-17 Avidor Shulman Food products for diabetics
AU2005270831B2 (en) 2004-08-10 2011-08-25 Enzymotec Ltd. Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions

Also Published As

Publication number Publication date
AU2005270831A1 (en) 2006-02-16
CN101039585B (zh) 2012-03-14
KR20070055528A (ko) 2007-05-30
RU2394576C2 (ru) 2010-07-20
US8772270B2 (en) 2014-07-08
BRPI0513461A2 (pt) 2011-05-10
CN101039585A (zh) 2007-09-19
EP1796726A2 (en) 2007-06-20
WO2006016363A2 (en) 2006-02-16
IL181234A0 (en) 2007-07-04
JP2008509904A (ja) 2008-04-03
RU2007108771A (ru) 2008-09-20
US20070196440A1 (en) 2007-08-23
AU2005270831B2 (en) 2011-08-25
WO2006016363A3 (en) 2006-03-16
KR101323513B1 (ko) 2013-10-29

Similar Documents

Publication Publication Date Title
US8772270B2 (en) Treatment methods requiring phyto-ingredients
Berger et al. Plant sterols: factors affecting their efficacy and safety as functional food ingredients
US8507466B2 (en) Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
AU2009200897B2 (en) Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides
CA2602643C (en) Composition for improving blood cholesterol levels
US6277431B1 (en) Anticholesterolemic edible oil
ES2981311T3 (es) Mezclas de aceites y su uso en composiciones
Bartnikowska Biological activities of phytosterols with particular attention to their effects on lipid metabolism
KR100548602B1 (ko) 항콜레스테롤 식용 기름
US20020192318A1 (en) Anticholesterolemic edible oil
US8993551B2 (en) Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
He et al. Application of phytosterols in management of plasma cholesterol
Qian et al. Phytosterols
CA2538494C (en) Composition for modulating blood parameters
AU2001236584A1 (en) Anticholesterolemic edible oil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111209

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121016

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121022

R150 Certificate of patent or registration of utility model

Ref document number: 5118965

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees